

## Expected submission timelines

2023 →
<b>Kevzara<sup>A</sup></b> Polyarticular juvenile idiopathic arthritis

2024 →	
<b>Dupixent<sup>A</sup></b> COPD	<b>tolebrutinib</b> SPMS
<b>Sarclisa</b> 1L Newly Diag. MM Tt (IMROZ)	<b>venglustat</b> GM2 gangliosidosis
<b>Sarclisa</b> 1L Newly Diag. MM Te (GMMG)	<b>rilzabrutinib</b> ITP
<b>tusamitamab ravtansine</b> 2/3L NSCLC	<b>fitusiran</b> Hemophilia A/B
<b>tolebrutinib</b> RMS	<b>MenQuadfi</b> 6w+

2025 and beyond →	
<b>Dupixent<sup>A</sup></b> CPUO	<b>frexalimab</b> MS
<b>Dupixent<sup>A</sup></b> Bullous pemphigoid	<b>Nexvazyme</b> Pompe Disease - Infantile Onset
<b>Kevzara<sup>A</sup></b> Systemic Juvenile Arthritis	<b>venglustat</b> Gaucher Type 3
<b>amlitelimab</b> Atopic Dermatitis	<b>venglustat</b> Fabry Disease
<b>itepekimab<sup>A</sup></b> COPD	<b>fitusiran</b> Hemophilia A/B ped
<b>Sarclisa</b> Smoldering MM	<b>VRVg</b> Purified vero rabies vaccine
<b>Sarclisa SubQ</b> 3L RR MM (IRAKLIA)	<b>SP0125</b> RSV toddler
<b>tolebrutinib</b> PPMS	<b>SP0202</b> Pneumococcal
	<b>SP0218</b> Yellow fever

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines

As of June 30, 2023. For collaborations see slide 59. For abbreviations see slide 60.  
Excluding Phase 1 and 2 (without Proof of Commercial Concept); Projects within a specified year are not arranged by submission timing.